Download PDF
Thromb Haemost 2008; 100(03): 420-428
DOI: 10.1160/TH08-04-0210
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate

Bianca F. Glauser
1   Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho
2   Instituto de Bioquímica Médica
,
Mariana S. Pereira
1   Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho
3   Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Cidade Universitária, Ilha do Fundão, Rio de Janeiro, RJ, Brazil
,
Robson Q. Monteiro
2   Instituto de Bioquímica Médica
,
Paulo A. S. Mourão
1   Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho
2   Instituto de Bioquímica Médica
› Author AffiliationsFinancial support: This work was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).
Further Information

Publication History

Received: 04 April 2008

Accepted after major revision: 10 July 2008

Publication Date:
22 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

Fucosylated chondroitin sulfate is a glycosaminoglycan from sea cucumber composed of a chondroitin sulfate-like core with branches of sulfated fucose. This glycosaminoglycan has high anticoagulant and antithrombotic activities. Its serpin-dependent anticoagulant activity is mostly due to activating thrombin inhibition by heparin cofactor II. Here, we evaluated the anticoagulant activity of fucosylated chondroitin sulfate using antithrom-bin- and heparin cofactor II-free plasmas. In contrast to mammalian heparin, the invertebrate glycosaminoglycan is still able to prolong coagulation time and delay thrombin and factor Xa generation in serpin-free plasmas. These observations suggest that fucosylated chondroitin sulfate has a serpin-independent anticoagulant effect. We further investigated this effect using purified blood coagulation proteins. Clearly, fucosylated chondroitin sulfate inhibits the intrinsic tenase and prothrombinase complexes, which are critical for thrombin generation. It is possible

that the invertebrate chondroitin sulfate inhibits interactions between cofactor Va and factor Xa. We also employed chemically modified polysaccharides in order to trace a structure versus activity relationship. Removal of the sulfated fucose branches, but not reduction of the glucuronic acid residues to glucose, abolished its activity. In conclusion, fucosylated chondroitin sulfate has broader effects on the coagulation system than mammalian glycosaminoglycans. In addition to its serpin-dependent inhibition of coagulation protease, it also inhibits the generation of factor Xa and thrombin by the tenase and prothrombinase complexes, respectively. In plasma systems, the serpin-independent anticoagulant effect of fucosylated chondroitin sulfate predominates over its serpin-dependent action. This glycosaminoglycan opens new avenues for the development of antithrombotic agents.

Keywords

Glycosaminoglycan - tenase complex - prothrombinase complex - sea cucumber - heparin
 

  • References

  • 1 American Heart Association 2002. Heart and Stroke. Statistical update.
    PubMedGoogle Scholar
  • 2 Friedman RJ. Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty. J Am Acad Orthop Surg 2007; 15: 148-155.
    CrossrefPubMedGoogle Scholar
  • 3 Mourão PAS, Pereira MS. Searching for alternatives to heparin. Trends Cardiovasc Med 1999; 09: 225-232.
    CrossrefPubMedGoogle Scholar
  • 4 Farias WRL, Valente AP, Pereira MS. et al. Structure and anticoagulant activity of sulfated galactans - Isolation of a unique sulfated galactan from the red algae Botryocladia occidentalis and comparison of its anticoagulant action with that of sulfated galactans from invertebrates. J Biol Chem 2000; 275: 29299-29307.
    CrossrefPubMedGoogle Scholar
  • 5 Mulloy B, Mourão PA, Gray E. Structure/function studies of anticoagulant sulphated polysaccharides using NMR. J Biotechnol 2000; 77: 123-135.
    CrossrefPubMedGoogle Scholar
  • 6 Mourão PA, Pereira MS, Pavão MS. et al. Structure and anticoagulant activity of a fucosylated chondroitin sulfate from echinoderm. J Biol Chem 1996; 271: 23973-23984.
    CrossrefPubMedGoogle Scholar
  • 7 Pacheco RG, Vicente CP, Zancan P. et al. Different antithrombotic mechanisms among glycosaminoglycans revealed with a new fucosylated chondroitin sulfate from an echinoderm. Blood Coagul Fibrinolysis 2000; 11: 563-573.
    CrossrefPubMedGoogle Scholar
  • 8 Fonseca RJC, Mourão PA S. Fucosylated chondroitin sulfate as a new antithrombotic agent. Thromb Haemost 2006; 96: 822-829.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Zancan P, Mourão PA. Venous and arterial thrombosis in rat models: dissociation of the antithrombotic effects of glycosaminoglycans. Blood Coagul Fibrinolysis 2004; 15: 45-54.
    CrossrefPubMedGoogle Scholar
  • 10 Astermark J, Hogg PJ, Bjork I. et al. Effects of gamma-carboxyglutamic acid and epidermal growth factor-likemodules of factor IX on factor X activation. Studies using proteolytic fragments of bovine factor IX. J Biol Chem 1992; 267: 3249-3256.
    PubMedGoogle Scholar
  • 11 Ngai PK, Chang JY. A novel one-step purification of human alpha-thrombin after direct activation of crude prothrombin enriched from plasma. Biochemistry J 1991; 280: 805-806.
    PubMedGoogle Scholar
  • 12 Barrow RT, Parker ET, Krishnaswamy S. et al. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem 1994; 269: 26796-26800.
    PubMedGoogle Scholar
  • 13 Pereira MS, Melo FR, Mourão PA S. Is there a correlation between structure and anticoagulant action of sulfated galactans and sulfated fucans?. Glycobiology 2002; 12: 573-580.
    CrossrefPubMedGoogle Scholar
  • 14 Butenas S, Mann KG. Blood coagulation. Biochemistry 2002; 67: 3-12.
    PubMedGoogle Scholar
  • 15 Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-518.
    CrossrefPubMedGoogle Scholar
  • 16 Stenflo J. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 1991; 78: 1637-1651.
    PubMedGoogle Scholar
  • 17 Rezaie AR. Heparin-binding exosite of factor Xa. Trends Cardiovasc Med 2000; 10: 333-338.
    CrossrefPubMedGoogle Scholar
  • 18 Sheehan JP, Sadler JE. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci USA 1994; 91: 5518-5522.
    CrossrefPubMedGoogle Scholar
  • 19 Rezaie AR. Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding. J Biol Chem 2000; 275: 3320-3327.
    CrossrefPubMedGoogle Scholar
  • 20 Sheehan JP, Walke EN. Depolymerized holothurian glycosaminoglycan and heparin inhibit the intrinsic tenase complex by a common antithrombin-independent mechanism. Blood 2006; 107: 3876-3882.
    CrossrefPubMedGoogle Scholar
  • 21 Kishimoto TK, Viswanathan K, Ganguly T. et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358: 2457-2467.
    CrossrefPubMedGoogle Scholar
  • 22 Björk I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982; 48: 161-182.
    CrossrefPubMedGoogle Scholar
  • 23 Bauer KA. New anticoagulants. Hematology Am Soc Hematol Educ Program 2006; 450-456.
    PubMedGoogle Scholar
  • 24 Bauer KA. New anticoagulants: anti IIa vs anti Xa--is one better?. J Thromb Thrombolysis 2006; 21: 67-72.
    CrossrefPubMedGoogle Scholar
  • 25 Wienbergen H, Zeymer U. Management of acute coronary syndromes with fondaparinux. Vasc Health Risk Manag 2007; 03: 321-329.
    PubMedGoogle Scholar
  • 26 Eriksson BI, Dahl OE, Büller HR. et al. BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005; 03: 103-111.
    CrossrefPubMedGoogle Scholar
  • 27 Holrner E. Heparin. Chemical and biological properties, clinical applications 1989; 575-595.
    PubMedGoogle Scholar
  • 28 Leizorovicz A, Haugh MC, Chapuis FR. et al. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-920.
    CrossrefPubMedGoogle Scholar
  • 29 Nurmohamed MT, Rosendaal FR, Büller HR. et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-156.
    CrossrefPubMedGoogle Scholar
  • 30 Thomas DP, Merton RE, Barrowcliffe TW. et al. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost 1982; 47: 244-248.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Rand MD, Lock JB, van’tVeer C. et al. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-3445.
    PubMedGoogle Scholar
  • 32 Hockin MF, Jones KC, Everse SJ. et al. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322-18333.
    CrossrefPubMedGoogle Scholar
  • 33 Anderson JA, Fredenburgh JC, Stafford AR. et al. Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase. J Biol Chem 2001; 276: 9755-9761.
    CrossrefPubMedGoogle Scholar
  • 34 Sie P, Ofosu F, Fernandez F. et al. Activerole of anti-thrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulfated polysaccharides. Br J Haematol 1986; 64: 707.
    CrossrefPubMedGoogle Scholar
  • 35 Nagase H, Enjyoji K, Minamiguchi K. et al. De-polymerized holothurian glycosaminoglycan with novel anticoagulant actions: antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. Blood 1995; 85: 1527-1534.
    PubMedGoogle Scholar
  • 36 Buchanan MR, Ofosu FA, Fernandez F. et al. Lack of relationship between enhanced bleeding induced by heparin and other sulfated polysaccharides and enhanced catalysis of thrombin inhibition. Semin Thromb Hemost 1986; 12: 324-327.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 He L, Vicente CP, Westrick RJ. et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J Clin Invest 2002; 109: 213-219.
    CrossrefPubMedGoogle Scholar